Aurobindo Pharma has reported that Aurobindo Pharma USA, the company’s subsidiary has voluntarily recalled two lots of the anti-hypertensive Lisinopril tablets, 30 mg, from the US market due to a labeling error.
The company initiated the recall on April 9 as the label on the bottles of the drug mentioned the incorrect strength. The recall has been classified under Class-III, which the USFDA defines as products that are unlikely to cause any adverse health reaction but violate FDA labeling or manufacturing laws.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
